Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT02439138
Other study ID # 15-040
Secondary ID ISR IN-US-313-16
Status Suspended
Phase Phase 2
First received April 29, 2015
Last updated March 21, 2016
Start date October 2015
Est. completion date May 2020

Study information

Verified date March 2016
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This research study is evaluating a drug called idelalisib (formerly known as GS-1101 or CAL-101) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).


Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, idelalisib, to learn whether idelalisib works in treating a specific cancer. "Investigational" means that idelalisib is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if idelalisib is effective for treating different types of cancer. Idelalisib has already been approved in the US by the FDA to treat patients with relapsed chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma.

Idelalisib is a newly discovered drug that is being developed as an anti-cancer agent. This drug has been used in laboratory experiments and other research studies in B-cell malignancies and information from those other research studies suggests that idelalisib may help to target the tumor cells in B-cell malignancies, including WM. B cells are a type of white blood cell responsible for making antibodies.

In this research study, the investigators are testing the safety and efficacy of idelalisib as a treatment option for relapsed or refractory Waldenstrom's Macroglobulinemia.


Recruitment information / eligibility

Status Suspended
Enrollment 30
Est. completion date May 2020
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants must meet the following criteria on screening examination to be eligible to participate in the study:

- Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's macroglobulinemia (Owen 2003; Kyle 2003).

- Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is required.

- Have received at least one prior therapy for WM.

- Age =18 years.

- ECOG performance status <2 (see Appendix A.).

- Participants must have normal organ and marrow function as defined below:

- Absolute neutrophil count > 1,000/mm3

- Platelets > 50,000/mm3

- Hemoglobin > 8 g/dL

- Total bilirubin =1.5 mg/dL or < 2 mg/dL if attributable to hepatic infiltration by neoplastic disease

- AST (SGOT) and ALT (SGPT) < 2.5 X institutional upper limit of normal

- Creatinine = 2 mg/dL

- Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.

- Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study:

1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed.

- Able to adhere to the study visit schedule and other protocol requirements.

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent the participant from signing the informed consent form

- Concurrent use of any other anti-cancer agents or treatments or any other study agents

- Prior exposure to idelalisib

- Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, ECG finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of Idelalisib; or impair the assessment of study results

- Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy

- Known central nervous system lymphoma

- Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening

- New York Heart Association classification III or IV heart failure.

- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

- Known history of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV) infection

- Lactating or pregnant women

- Inability to swallow capsules

- History of non-compliance to medical regimens

- Unwilling or unable to comply with the protocol

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
GS-1101


Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute Gilead Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate (ORR) ORR measured by decrease in serum IgM levels 3 years Yes
Secondary Number of Adverse Events Assess the safety and tolerability of idelalisib 2 years Yes
Secondary Rate of complete response (CR) CR measured by decrease in serum IgM levels 3 years Yes
Secondary Rate of Very Good Partial Response (VGPR) VGPR measured by decrease in serum IgM levels 3 years Yes
Secondary Rate of Partial Response (PR) PR measured by decrease in serum IgM levels 3 years Yes
Secondary Rate of Minimal Response Minimal response measured by decrease in serum IgM levels 3 years Yes
Secondary Rate of Stable Disease Stable disease measured by serum IgM levels 3 years Yes
Secondary Rate of Progressive Disease Progressive disease measured by serum IgM levels 4 years Yes
Secondary Progression free survival (PFS) PFS measured in months from initiation of therapy 4 years Yes
Secondary Median Disease Free Survival (DFS) DFS measured in months from achievement of CR 4 years Yes
Secondary Median time to progression (TTP) TTP measured in months from initiation of therapy 2 Years Yes
Secondary Median Duration of Response (DOR) DOR measured in months from achievement of CR 4 years Yes
Secondary Median Time to Next Therapy (TTNT) TTNT measured in months from initiation of therapy 4 years Yes
Secondary MYD88 L265P burden in response to idelalisib in patients with WM Measured by PCR 2 Years Yes
Secondary Association between depth of response and quantification of MYD88 L265P burden Measured by PCR 2 Years Yes
Secondary Association between presence of CXCR4-WHIM-like mutations and response to idelalisib Measured by Sanger Sequencing 2 Years Yes
See also
  Status Clinical Trial Phase
Completed NCT02566265 - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Phase 2
Completed NCT00422656 - Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00165295 - Sildenafil Citrate in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00150462 - Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies Phase 1
Terminated NCT00142168 - CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT01470196 - Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00250926 - Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Phase 2
Terminated NCT03225716 - A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia Phase 1
Terminated NCT01744912 - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Phase 1
Completed NCT02363439 - Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 Phase 1/Phase 2
Completed NCT00976248 - Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia Phase 2
Terminated NCT00575965 - Simvastatin in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00919139 - S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. N/A
Completed NCT01614821 - Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia Phase 2
Active, not recruiting NCT01078974 - Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia Phase 1
Completed NCT00481871 - Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Phase 1/Phase 2
Completed NCT00142116 - Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT02092909 - Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Phase 1/Phase 2
Completed NCT00807677 - A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies Phase 1
Completed NCT01046006 - Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Phase 2